Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBM-007 extension study in wet AMD
NCT04640272Phase 2Completed
- Sponsor
- Ribomic Inc.
- Start
- Nov 2020
- Primary completion
- Nov 2021
- Modality
- RNA Aptamers, DNA Aptamers
- Countries
- 1
01
Overview
A Phase 2 trial of umedaptanib pegol in exudative age-related macular degeneration, sponsored by Ribomic Inc.. Started Nov 2020; status: completed.
02
Drugs
umedaptanib pegol
03
Conditions
exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT04640272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04640272.